BREO ELLIPTA®

Drug Information Related Patent

Hold Company

GLAXOSMITHKLINE

Learn More

Dosage and Administration

POWDER;INHALATION

Specification

0.1MG/INH;EQ 0.025MG BASE/INH
0.2MG/INH;EQ 0.025MG BASE/INH
0.05MG/INH;EQ 0.025MG BASE/INH

Indication

BREO ELLIPTA® is suitable for the maintenance treatment of chronic obstructive pulmonary disease and the maintenance treatment of asthma.

Use

Instructions for Use

API

FLUTICASONE FUROATE
VILANTEROL TRIFENATATE

API Structure

We Supply

FLUTICASONE FUROATE

Note:

In-house Standard
Facility GMP
USMF/CDE/ASMF/CEP

VILANTEROL TRIFENATATE

Note:

Commercial

null

Note:

null

Drug Patent

Patent No	Expiration Date
11116721	2029/2/26
11116721*PED	2029/8/26
7439393	2025/5/21
7439393*PED	2025/11/21
8113199	2027/10/23
8113199*PED	2028/4/23
8161968	2028/2/5
8161968*PED	2028/8/5
8511304	2027/6/14
8511304*PED	2027/12/14
8534281	2030/3/8
8534281*PED	2030/9/8
8746242	2030/10/11
8746242*PED	2031/4/11
9333310	2027/10/2
9333310*PED	2028/4/2

API Patent

Patent No	Expiration Date
7439393	2025/5/21
7439393*PED	2025/11/21

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION